このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

HBM Holdings 過去の業績

過去基準チェック /26

HBM Holdingsは、平均年間10.4%の収益成長を遂げていますが、 Biotechs業界の収益は、年間成長しています。収益は、平均年間11.7% 58.1%収益成長率で成長しています。 HBM Holdingsの自己資本利益率は19%であり、純利益率は25.5%です。

主要情報

10.4%

収益成長率

40.6%

EPS成長率

Biotechs 業界の成長	11.0%
収益成長率	58.1%
株主資本利益率	19.0%
ネット・マージン	25.5%
前回の決算情報	31 Dec 2023

Recent updates

HBM Holdings (HKG:2142) Seems To Use Debt Quite Sensibly

May 23

Take Care Before Jumping Onto HBM Holdings Limited (HKG:2142) Even Though It's 28% Cheaper

Apr 12

HBM Holdings Limited (HKG:2142) Surges 25% Yet Its Low P/S Is No Reason For Excitement

Jan 01

We're Not Very Worried About HBM Holdings' (HKG:2142) Cash Burn Rate

Feb 08

HBM Holdings (HKG:2142) Is In A Strong Position To Grow Its Business

May 30

Revenue Downgrade: Here's What Analysts Forecast For HBM Holdings Limited (HKG:2142)

Apr 07

Here's What Analysts Are Forecasting For HBM Holdings Limited (HKG:2142) After Its Full-Year Results

Mar 31

What Type Of Shareholders Own The Most Number of HBM Holdings Limited (HKG:2142) Shares?

Mar 10

収支内訳

HBM Holdings の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。

収益と収入の歴史

SEHK:2142 収益、費用、利益 ( )USD Millions
日付	収益	収益	G+A経費	研究開発費
31 Dec 23	90	23	21	45
30 Sep 23	72	-19	21	62
30 Jun 23	54	-61	21	80
31 Mar 23	47	-99	24	108
31 Dec 22	41	-137	27	135
30 Sep 22	35	-143	35	142
30 Jun 22	30	-149	43	150
31 Mar 22	17	-144	42	128
31 Dec 21	4	-138	40	107
30 Sep 21	7	-224	46	94
30 Jun 21	10	-310	53	81
31 Mar 21	12	-303	50	68
31 Dec 20	14	-296	46	55
30 Sep 20	13	-187	28	46
30 Jun 20	11	-78	11	37
31 Mar 20	8	-73	11	43
31 Dec 19	5	-67	11	49
31 Dec 18	1	-35	6	32

質の高い収益: 2142 非現金収入のレベルが高いです。

利益率の向上: 2142過去に利益を上げました。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: 2142過去 5 年間で収益を上げており、収益は年間10.4%増加しています。

成長の加速: 2142は昨年収益を上げたため、収益成長率を 5 年間の平均と比較することは困難です。

収益対業界: 2142昨年収益を上げたため、昨年の収益成長をBiotechs業界 ( 22.1% ) と比較することは困難です。

株主資本利益率

高いROE: 2142の自己資本利益率 ( 19% ) は低いとみなされます。

HBM Holdings 過去の業績

過去 基準チェック /26

主要情報

最近の業績更新

Full year 2023 earnings released: EPS: US$0.03 (vs US$0.19 loss in FY 2022)

HBM Holdings Limited to Report Fiscal Year 2023 Results on Mar 28, 2024

First half 2023 earnings released: EPS: US$0.004 (vs US$0.10 loss in 1H 2022)

HBM Holdings Limited to Report First Half, 2023 Results on Aug 28, 2023

Full year 2022 earnings: EPS and revenues miss analyst expectations

First half 2022 earnings released: US$0.10 loss per share (vs US$0.084 loss in 1H 2021)

Recent updates

HBM Holdings (HKG:2142) Seems To Use Debt Quite Sensibly

Investor sentiment improves as stock rises 17%

New minor risk - Market cap size

Investor sentiment deteriorates as stock falls 16%

Take Care Before Jumping Onto HBM Holdings Limited (HKG:2142) Even Though It's 28% Cheaper

HBM Holdings Limited, Annual General Meeting, Jun 06, 2024

Full year 2023 earnings released: EPS: US$0.03 (vs US$0.19 loss in FY 2022)

HBM Holdings Limited to Report Fiscal Year 2023 Results on Mar 28, 2024

Harbour BioMed Announces IND Clearance for HBM9027 in the U.S

HBM Holdings Limited Provides Earnings Guidance for the Year Ended 31 December 2023

HBM Holdings Limited (HKG:2142) Surges 25% Yet Its Low P/S Is No Reason For Excitement

HBM Holdings Limited Announces Executive Changes

New major risk - Revenue and earnings growth

Forecast to breakeven in 2023

Consensus EPS estimates upgraded to US$0.05 loss

First half 2023 earnings released: EPS: US$0.004 (vs US$0.10 loss in 1H 2022)

Harbour BioMed Announces US IND Clearance of Its First ADC Program HBM9033 in Solid Tumors

HBM Holdings Limited to Report First Half, 2023 Results on Aug 28, 2023

Harbour BioMed Appoints Dr. Albert R. Collinson as Independent Non-Executive Director

New minor risk - Share price stability

HBM Holdings Limited Announces Board Changes

National Medical Products Administration of China Accepts Biologics License Application for HBM Holdings Limited's Batoclimab for Treatment of gMG

HBM Holdings Limited Appoints Steve Arkinstall as Chief Scientific Advisor of Nona Biosciences

Harbour BioMed Announces First Patient Dosed in Phase I Study of First-In-Class Anti-B7H7 (HHLA2) Antibody HBM1020

Harbour BioMed Reports Results of Phase Ib Clinical Trial of Porustobart in Combination of Toripalimab in Patients with Hepatocellular Carcinoma at ASCO 2023

Consensus revenue estimates increase by 28%

Consensus estimates of losses per share improve by 36%

Full year 2022 earnings: EPS and revenues miss analyst expectations

Hbm Holdings Limited Announces Food and Drug Administration of the United States Investigational New Drug Clearance for HBM1020 Clinical Trial Initiation

Hbm Holdings Limited Announces Results from Phase I Clinical Trial of Porustobart (Hbm4003)In Combination with Toripalimab in Advanced Melanoma

WuXi Vaccines (Hong Kong) Limited entered into an agreement to acquire Manufacturing facility in Suzhou from HBM Holdings Limited (SEHK:2142).

Less than half of directors are independent

HBM Holdings Limited Appoints Mr. Weihao Xu as Chief Business Officer

Harbour BioMed Announces Dosing of First Patient in Phase I Trial of B7H4x4-1BB Bispecific Antibody in the United States

Hbm Holdings Limited Announces Closing the Study of Phase III Clinical Trial of Tanfanercept (Hbm9036)

Harbour BioMed Announces First Subject Dosed in Phase I Study of Next-Gen Anti-TSLP Fully Human Monoclonal Antibody

Consensus forecasts updated

First half 2022 earnings released: US$0.10 loss per share (vs US$0.084 loss in 1H 2021)

Hbm Holdings Limited Announces Completion of First Dosing of Last Patient with Hbm4003 Phase Ib Trial

Harbour BioMed Announces the Preclinical Results of Porustobart

HBM Holdings Limited to Report First Half, 2022 Results on Aug 31, 2022

Harbour BioMed Announces IND Clearance for B7H4x4-1BB Bispecific Antibody by the U.S. Food and Drug Administration

HBM Holdings Limited Announces IND Approval for Commencement of Phase I Trial of B7H4X4-1BB Bispecific Antibody in China

Hbm Holdings Limited Announces Data Release of Next-Gen Ctla-4 Antibody At Asco 2022

HBM Holdings Limited Announces That Dosing of First Patient in Phase I Trial of B7h4x4-1Bb Bispecific Antibody Hbm7008 Has Been Completed

Consensus forecasts updated

Hbm Holdings Limited Announces Data Release Forecast of Hbm4003 At ASCO 2022

HBM Holdings Limited Announces Board Changes

Harbour BioMed Appoints Dr. Alexander A. Zukiwski to its Scientific Advisory Board

Less than half of directors are independent

Harbour BioMed Appoints Humphrey Gardner as Chief Medical Officer

Consensus revenue estimates increase by 302%

Harbour BioMed Announces Approval for Phase I Trial of B7H4x4-1BB Bispecific Antibody in Australia

HBM Holdings Limited Announces Approval of Investigational New Drug Application for HBM9378 by National Medical Products Administration of the People's Republic of China

We're Not Very Worried About HBM Holdings' (HKG:2142) Cash Burn Rate

HBM Holdings Limited Announces Completion of First Interim Analysis of Phase III Clinical Trial of Tanfanercept (HBM9036)

Founder recently bought HK$1.0m worth of stock

HBM Holdings Limited Announces Completion of First Dosing of First Patient with Two HBM4003 Phase I Trials

HBM Holdings Limited Announces Completion of First Dosing of First Patient with Batoclimab (Hbm9161) Phase III Trial for Treatment of Generalized Myasthenia Gravis

Harbour Biomed Announces Phase I Study Positive Results on Next-Generation Anti-CTLA-4 Antibody HBM4003

HBM Holdings Limited Announces Chinese Regulatory Approval of Two Ind Applications for Next-Generation Anti-Ctla-4 Antibody Hbm4003

First half 2021 earnings released: US$0.084 loss per share (vs US$0.39 loss in 1H 2020)

HBM Holdings Limited Receives National Medical Products Administration of the People's Republic of China Approval of Investigational New Drug Application to Begin Phase II Clinical Trial of HBM9161 in Chronic Inflammatory Demyelinating Polyneuropathy

Harbour BioMed Announces Dosing of First Patient of Next-Generation Anti-CTLA-4 Antibody in Combination with PD-1 Antibody in Patients with NSCLC

HBM Holdings Limited Provides Update on Ongoing Clinical Studies Forbatoclimab (HBM9161)

HBM Holdings (HKG:2142) Is In A Strong Position To Grow Its Business

Harbour BioMed Announces Dosing of First Patient in Australia for Phase Ib/IIa Clinical Study of its Next-Generation Anti-CTLA-4 Antibody

Executive Director, Chief Strategy Officer & Head of U.S. Operations has left the company

Full year 2020 earnings released: US$1.69 loss per share (vs US$0.57 loss in FY 2019)

過去基準チェック /26